Skip to main content

  • Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial

    • Posted: 10/01/2024
    • Author:

      Antonio Popolo Rubbio, Luca Testa, Carlo A. Pivato, Damiano Regazzoli, Raffaele Piccolo, Giovanni Esposito, Carmine Musto, Lorenzo Scalia, Andrea Pacchioni, Carlo Briguori, Luigi Lucisano, Leonardo De Luca, Federico Conrotto, Francesco Tartaglia, Alessia C. Latini, Kamil Stankowski, Mauro Chiarito, Gennaro Sardella, Ciro Indolfi, Francesco Bedogni, Bernhard Reimers, Gianluigi Condorelli and Giulio G. Stefanini

    • NewsCRM2024

    Abstract

    Background

    Previous studies have investigated a 1 to 6-month short dual antiplatelet therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting-stents to reduce bleeding events.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details